Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Liwen Xiong

Feasibility of Continuing Crizotinib Therapy After RECIST-PD in Advanced Non-Small Cell Lung Cancer Patients With ALK/ROS-1 Mutations

Journal of Cancer
Oncology
2018English

Expression of Concern: Knockdown of eIF3d Inhibits Cell Proliferation Through G2/M Phase Arrest in Non-Small Cell Lung Cancer

Medical Oncology
MedicineCancer ResearchOncologyHematology
2018English

Related publications

Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer With ALK-rearrangement: A Brief Report

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Efficacy and Safety of Crizotinib Among Chinese EML4-ALK-Positive, Advanced-Stage Non-Small Cell Lung Cancer Patients

PLoS ONE
Multidisciplinary
2014English

Heterogeneous Responses and Resistant Mechanisms to Crizotinib in ALK -Positive Advanced Non-Small Cell Lung Cancer

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

174P: Comparison of Cardiovascular Effects of Crizotinib and Chemotherapy in Patients (Pts) With ALK-positive (+) Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer

American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer ResearchOncology
2015English

P104 Anti-Pd-1 Combination Therapy in Second or Later Lines in Patients With Advanced Non Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-29 Crizotinib in Advanced Lung Adenocarcinoma Patients With ALK or ROS-1 Rearrangement: Is It the Same?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2016English

Cost-Effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-Cell Lung Cancer in China

PLoS ONE
Multidisciplinary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy